

### In the Claims

Please amend and withdraw claims as indicated in the following listing of claims. This listing of the claims will replace all prior versions, and listings, of claims in the application:


Claims 31-58 are pending in this Application.

Claims 32-36, 39-49, and 51-53 were previously presented.

Claims 54-58 are withdrawn and are subject to rejoinder.

Claims 31, 37, 38, 50, 54, and 57 are currently amended.

31. (**currently amended**) A compound according to formula I,



**I**

or a pharmaceutically acceptable salt or a stereoisomer, thereof, wherein,

A is a five- to ten-membered ring containing up to three heteroatoms; provided A is not a saturated alicyclic when X<sup>2</sup> is =N-, X<sup>3</sup> is -O-, and A is a pyridin-4-yl;

R<sup>1</sup> is selected from -H, halo, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, -S(O)<sub>0.2</sub>R<sup>4</sup>, -SO<sub>2</sub>N(R<sup>4</sup>)R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -C(=O)R<sup>4</sup>, -C(=NR<sup>5</sup>)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, alkoxy, C<sub>1-6</sub> alkyl, aryl, aryl C<sub>1-6</sub> alkyl, heterocyclyl, and heterocyclyl C<sub>1-6</sub> alkyl;

two adjacent of R<sup>1</sup>, together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to four of R<sup>10</sup>;

R<sup>2</sup> and R<sup>3</sup>, together with the annular atoms to which they are attached, form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to five of R<sup>6</sup>;

each R<sup>4</sup> is selected from -H; C<sub>1-6</sub> alkyl optionally substituted with 1, 2, or 3 halogen; C<sub>1-6</sub> alkyl optionally substituted with alkoxy; C<sub>1-6</sub> alkyl substituted with amino where the

amino is optionally substituted with one or groups selected from methyl, ethyl,  $-\text{CH}_2\text{CH}_2\text{OCH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$ , and *N*-methyl-pyrrolidin-3-yl; aryl; aryl  $\text{C}_{1-6}$  alkyl; heterocyclyl; and heterocyclyl  $\text{C}_{1-6}$  alkyl where the heterocyclyl is optionally substituted with alkyl, acyl,  $\text{NH}_2$ , alkylamino, dialkylamino, heterocyclyl, cyclohexyl,  $-\text{CH}_2\text{OCH}_3$ ,  $-\text{CH}_2\text{C}(\text{O})\text{NHCH}(\text{CH}_3)_2$ , or  $-\text{CH}_2\text{OCH}_3$ ;

two of  $\text{R}^4$ , when taken together with a common nitrogen to which they are attached, form an five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

each  $\text{R}^5$  is selected from  $-\text{H}$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{OR}^4$ ,  $-\text{S}(\text{O})_{0-2}\text{R}^4$ ,  $-\text{CO}_2\text{R}^4$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl, and  $\text{C}_{2-6}$  alkynyl;

Y is  $=\text{N}-$  or  $=\text{C}(\text{H})-\text{C}(\text{R}^8)-$ ;

$\text{X}^1$  and  $\text{X}^2$  are each independently either  $=\text{N}-$  or  $=\text{C}(\text{R}^9)-$ ;

$\text{X}^3$  is selected from  $-\text{N}(\text{R}^7)-$ ,  $-\text{O}-$ , and  $-\text{S}-$ ;

$\text{R}^7$  is hydrogen;

each of  $\text{R}^6$ ,  $\text{R}^8$ , and  $\text{R}^{10}$  is independently selected from  $-\text{H}$ , halo, trihalomethyl,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{OR}^4$ ,  $-\text{N}(\text{R}^4)\text{R}^4$ ,  $-\text{S}(\text{O})_{0-2}\text{R}^4$ ,  $-\text{SO}_2\text{N}(\text{R}^4)\text{R}^4$ ,  $-\text{CO}_2\text{R}^4$ ,  $-\text{C}(=\text{O})\text{N}(\text{R}^4)\text{R}^4$ ,  $-\text{C}(=\text{NR}^5)\text{N}(\text{R}^4)\text{R}^4$ ,  $-\text{C}(=\text{NR}^5)\text{R}^4$ ,  $-\text{N}(\text{R}^4)\text{SO}_2\text{R}^4$ ,  $-\text{N}(\text{R}^4)\text{C}(\text{O})\text{R}^4$ ,  $-\text{C}(=\text{O})\text{R}^4$ , optionally substituted alkoxy,  $\text{C}_{1-6}$  alkyl, aryl, aryl  $\text{C}_{1-6}$  alkyl, heterocyclyl, and heterocyclyl  $\text{C}_{1-6}$  alkyl;

two adjacent of  $\text{R}^6$ , together with the annular atoms to which they are attached, can form a five- to seven-membered ring containing up to two heteroatoms; and


each  $\text{R}^9$  is independently selected from  $-\text{H}$ ; halo; trihalomethyl;  $-\text{CN}$ ;  $-\text{NO}_2$ ;  $-\text{OR}^4$ ;  $-\text{N}(\text{R}^4)\text{R}^4$ ;  $-\text{S}(\text{O})_{0-2}\text{R}^4$ ;  $-\text{SO}_2\text{N}(\text{R}^4)\text{R}^4$ ;  $-\text{CO}_2\text{R}^4$ ;  $-\text{C}(=\text{O})\text{N}(\text{R}^4)\text{R}^4$ ;  $-\text{C}(=\text{NR}^5)\text{N}(\text{R}^4)\text{R}^4$ ;  $-\text{C}(=\text{NR}^5)\text{R}^4$ ;  $-\text{N}(\text{R}^4)\text{SO}_2\text{R}^4$ ;  $-\text{N}(\text{R}^4)\text{C}(\text{O})\text{R}^4$ ;  $-\text{C}(=\text{O})\text{R}^4$ ; alkoxy;  $\text{C}_{1-6}$  alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl  $\text{C}_{1-6}$  alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with  $-\text{C}(\text{O})\text{Ot-Bu}$ ; and heterocyclyl  $\text{C}_{1-6}$  alkyl; provided when  $\text{R}^9$  is aryl, heteroaryl,  $-\text{C}(\text{H})=\text{C}(\text{H})\text{R}$  or  $-\text{C}(\text{H})=\text{NR}$ , where R is an

optionally substituted alkyl, cycloalkyl, heteroalicyclic, aryl, or heteroaryl, then Y is not =C(H)-.

32. **(previously presented)** The compound according to claim 31, wherein the five- to six-membered ring formed by R<sup>2</sup> and R<sup>3</sup> is an aryl or a heteroaryl optionally substituted with up to five of R<sup>6</sup>; or a pharmaceutically acceptable salt or stereoisomer, thereof.

33. **(previously presented)** The compound according to claim 32, wherein the five- to six-membered ring formed by R<sup>2</sup> and R<sup>3</sup> is phenyl or pyridyl optionally substituted with up to five of R<sup>6</sup>; or a pharmaceutically acceptable salt or stereoisomer, thereof.

34. **(previously presented)** The compound according to claim 33, of formula II,



or a pharmaceutically acceptable salt or stereoisomer, thereof.

35. **(previously presented)** The compound according to claim 34, wherein X<sup>1</sup> is =C(R<sup>9</sup>)-, X<sup>2</sup> is =N-, X<sup>3</sup> is -N(R<sup>7</sup>)-, and R<sup>7</sup> is hydrogen; or a pharmaceutically acceptable salt or stereoisomer, thereof.


36. **(previously presented)** The compound according to claim 35, wherein Y is =N-; or a pharmaceutically acceptable salt or stereoisomer, thereof.

37. **(currently amended)** The compound according to claim 36, wherein A is either a six- to ten-membered aryl or a five- to ten-membered heteroaryl containing up to three heteroatoms and where A is substituted with 1-5 R<sup>1</sup>; or a pharmaceutically acceptable salt or stereoisomer, thereof.

38. **(currently amended)** The compound according to claim 37, wherein A is either a six-membered aryl or a five- or six-membered heteroaryl containing up to three heteroatoms and where A is substituted with 1-5 R<sup>1</sup>; or a pharmaceutically acceptable salt or stereoisomer, thereof.

39. **(previously presented)** The compound according to claim 38, wherein  $R^1$  is selected from -H, halo, trihalomethyl, -CN, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, -SO<sub>2</sub>N(R<sup>4</sup>)R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, alkoxy, C<sub>1-6</sub> alkyl, heterocyclyl, and heterocyclyl C<sub>1-6</sub> alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.


40. **(previously presented)** The compound according to claim 39, of formula III,



III

wherein  $R^7$  is hydrogen and at least one of  $R^1$  is -OH; or a pharmaceutically acceptable salt or stereoisomer, thereof.

41. **(previously presented)** The compound according to claim 40, wherein the compound is either of Formula IIIa or IIIb:



or a pharmaceutically acceptable salt or stereoisomer, thereof.

42. **(previously presented)** The compound according to claim 41, wherein  $R^9$  is selected from -H; trihalomethyl; C<sub>1-6</sub> alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C<sub>1-6</sub> alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C<sub>1-6</sub> alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

43. **(previously presented)** The compound according to claim 42, wherein  $R^6$  is selected from -H, halo, trihalomethyl, -CN, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, -C(=O)R<sup>4</sup>, C<sub>1-6</sub> alkyl, heterocyclyl, heterocyclyl C<sub>1-6</sub> alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R<sup>6</sup>, together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

44. **(previously presented)** The compound according to claim 43, wherein  $R^6$  is selected from -H, halo, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, C<sub>1-6</sub> alkyl, heterocyclyl, heterocyclyl C<sub>1-6</sub> alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R<sup>6</sup>, together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

45. **(previously presented)** The compound according to claim 44, wherein at least one of R<sup>6</sup> is -OR<sup>4</sup> and R<sup>4</sup> is C<sub>1-6</sub> alkyl optionally substituted with 1, 2, or 3 halogen; C<sub>1-6</sub> alkyl optionally substituted with alkoxy; C<sub>1-6</sub> alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, and *N*-methyl-pyrrolidin-3-yl; and heterocyclyl where the heterocyclyl is optionally substituted with alkyl, acyl, NH<sub>2</sub>, alkylamino, dialkylamino, heterocyclyl, cyclohexyl, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>C(O)NHCH(CH<sub>3</sub>)<sub>2</sub>, or -CH<sub>2</sub>OCH<sub>3</sub>; or a pharmaceutically acceptable salt or stereoisomer, thereof.


46. **(previously presented)** The compound according to claim 45, wherein at least one of R<sup>1</sup> is halo or methyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

47. **(previously presented)** The compound according to claim 46, wherein R<sup>9</sup> is selected from -H, trihalomethyl, and C<sub>1-6</sub> alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

48. **(previously presented)** The compound according to claim 44, wherein at least one of  $R^6$  is  $-OR^4$  and  $R^4$  is heterocyclyl  $C_{1-6}$  alkyl where the heterocyclyl is a heteroalicyclic; or a pharmaceutically acceptable salt or stereoisomer, thereof.

49. **(previously presented)** The compound according to claim 48, wherein said heteroalicyclic is selected from the group consisting of dioxolanyl, piperidiny, piperaziny, 2-oxopiperaziny, 2-oxopiperidiny, 2-oxopyrrolidiny, 2-oxoazepiny, azepiny, 4-piperidony, pyrrolidiny, morpholiny, quinuclidiny, tetrahydrofuryl, tetrahydropyranly, thiamorpholiny, thiamorpholiny sulfoxide, 2,5-diazabicyclo[2.2.1]heptany, and thiamorpholiny sulfone; or a pharmaceutically acceptable salt or stereoisomer, thereof.

50. **(currently amended)** ~~The compound according to claim 44;~~ A compound according to Formula IIIa or IIIb



wherein

each  $R^1$  is independently selected from -H, halo, trihalomethyl, -CN,  $-OR^4$ ,  $-N(R^4)R^4$ ,  $-SO_2N(R^4)R^4$ ,  $-CO_2R^4$ ,  $-C(=O)N(R^4)R^4$ ,  $-C(=NR^5)N(R^4)R^4$ ,  $-C(=NR^5)R^4$ ,  $-N(R^4)SO_2R^4$ ,  $-N(R^4)C(O)R^4$ ,  $C_{1-6}$  alkyl, heterocyclyl, and heterocyclyl  $C_{1-6}$  alkyl;

$R^9$  is selected from -H, trihalomethyl;  $C_{1-6}$  alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidiny; aryl  $C_{1-6}$  alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with  $-C(O)Ot-Bu$ ; and heterocyclyl  $C_{1-6}$  alkyl; and






wherein at least one of  $R^6$  is  $-OR^4$  and  $R^4$  is alkyl substituted with at least one additional of alkoxy, amino, dialkylamino, and monoalkylamino where the amino of the monoalkylamino is further substituted with *N*-methyl-pyrrolidin-3-yl and where each alkyl of monoalkylamino and dialkylamino are independently optionally substituted with  $-NH_2$ ,  $-NHCH_3$ , or  $-N(CH_3)_2$ ; or a pharmaceutically acceptable salt or stereoisomer, thereof.

51. (previously presented) The compound according to claim 31, selected from Table 3; or a pharmaceutically acceptable salt or stereoisomer, thereof

**Table 3**






Entry	Name	Structure
10	4-{7,8-bis(methoxy)-1-[(4-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
12	4-(7,8-bis(methoxy)-1-{[4-(methoxy)phenyl]methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
13	4-{7,8-bis(methoxy)-1-[(2-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
14	4-{7,8-bis(methoxy)-1-[(3-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
15	4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**






Entry	Name	Structure
20	4-[1-{{3,4-bis(methoxy)phenyl}methyl}-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
21	4-(7,8-bis(methoxy)-1-{{3-(methoxy)phenyl}methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
22	4-[1-ethyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
25	4-[1-methyl-6,7,8-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
27	4-[7,8-bis(methoxy)-1-(trifluoromethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	








**Table 3**

Entry	Name	Structure
28	4-[1-(1-methylethyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
29	4-[7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
31	4-[1-methyl-6,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
32	4-[6,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
34	4-[6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
35	4-[1-methyl-7,8,9-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
36	4-[1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
37	2-methyl-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
38	4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-(methoxy)phenol	
39	4-{1-methyl-8-(methoxy)-7-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
40	2-(ethyloxy)-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
41	2-chloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
42	2-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
44	2-bromo-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
45	1-{[5-(4-hydroxyphenyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-1-yl)methyl}pyrrolidin-2-one	







**Table 3**

Entry	Name	Structure
54	4-{1-methyl-7-(methoxy)-8-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
55	4-{1-methyl-8-(methoxy)-7-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
58	4-[8-(ethoxy)-1-methyl-7-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
59	4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
60	4-[7-(ethoxy)-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
61	4-{1-methyl-8-(methoxy)-9-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
63	2-ethyl-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
64	4-(1-methyl-8-(methoxy)-9-[[1-methylpiperidin-4-yl)methyl]oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
65	4-(1-methyl-7-(methoxy)-8-[[1-methylpiperidin-4-yl)methyl]oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
66	4-[1,7-dimethyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	






**Table 3**

Entry	Name	Structure
67	1,1-dimethylethyl 4-[5-(4-hydroxyphenyl)-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-1-yl]piperidine-1-carboxylate	
69	2-chloro-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
70	2-fluoro-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
71	2-methyl-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
72	2-bromo-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
76	2-[(difluoromethyl)oxy]-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**






Entry	Name	Structure
78	4-[1,9-dimethyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
79	4-[6,9-difluoro-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
80	2-bromo-4-{1-methyl-8-(methoxy)-9-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
81	2-chloro-4-{1-methyl-8-(methoxy)-9-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
82	4-(7,8-bis(methoxy)-1-[[[(phenylmethyl)amino]methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
83	2,5-dimethyl-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
85	2,5-dichloro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
87	2-bromo-4-(1-methyl-8-(methoxy)-9-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
88	2-chloro-4-(1-methyl-7-(methoxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
89	4-[9-fluoro-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	



**Table 3**

Entry	Name	Structure
90	4-(1-methyl-8-(methoxy)-9- {[2-(methoxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i> ]isoquinolin-5- yl)phenol	
91	2-chloro-4-(1-methyl-8- (methoxy)-9- $\{[(1$ - methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i> ]isoquinolin-5- yl)phenol	
92	4-[6-bromo-1,7-dimethyl-8- (methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
93	4-[6-fluoro-1-methyl-7,8- bis(methoxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i> ]isoquinolin-5- yl]phenol	
94	4-[9-chloro-1,7-dimethyl-8- (methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	






**Table 3**

Entry	Name	Structure
95	2-chloro-4-[8-{{(1-ethylpiperidin-4-yl)methyl}oxy}-1-methyl-7-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
96	3-chloro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
97	4-(1-methyl-8,9-bis{{2-(methoxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
98	4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
99	2-chloro-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
100	2-bromo-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	






**Table 3**

Entry	Name	Structure
101	2-chloro-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
102	2-bromo-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
103	2-chloro-4-[1-methyl-8-({[1-(1-methylethyl)piperidin-4-yl]methyl}oxy)-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
104	4-[9-bromo-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
105	4-[7-chloro-9-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	






**Table 3**

Entry	Name	Structure
106	4-[8-{{(1-acetylpiperidin-4-yl)methyl}oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
107	4-[9-{{(1-acetylpiperidin-4-yl)methyl}oxy}-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-bromophenol	
108	2-chloro-4-(1-methyl-9-(methyloxy)-8-{{[2-(methyloxy)ethyl]oxy}}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
109	4-[7-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
110	2-chloro-4-(1-methyl-8,9-bis{{[2-(methyloxy)ethyl]oxy}}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**

Entry	Name	Structure
111	2-bromo-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
112	2-chloro-4-(1-methyl-8-(methyloxy)-9-{{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
113	2-bromo-4-(1-methyl-8-(methyloxy)-9-{{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
114	3-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
115	2-chloro-4-(1-methyl-7-(methyloxy)-8-{{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
116	2-bromo-4-(1-methyl-7-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
117	2-chloro-4-(1-methyl-7,8-bis{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
118	2-bromo-4-(1-methyl-7,8-bis{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
120	4-(6,9-difluoro-1-methyl-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
121	2-chloro-5-fluoro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
122	2-bromo-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
123	4-[9-fluoro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -benzo[ <i>c</i> ]indazol-5-yl]phenol	
125	3-fluoro-4-(1-methyl-7-(methyloxy)-8-{{2-(methyloxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
126	4-(6,9-difluoro-1-methyl-8-{{2-(methyloxy)ethyl}oxy}-[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-3-fluorophenol	
127	2-chloro-4-(6,9-difluoro-1-methyl-8-{{2-(methyloxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**






Entry	Name	Structure
128	2-chloro-4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
129	2-chloro-4-[6-chloro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
130	3-fluoro-4-(1-methyl-9-(methyloxy)-8-{{2-(methyloxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
131	2-chloro-4-(1,7-dimethyl-8-{{2-(methyloxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
132	3-fluoro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{{2-(methyloxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	








**Table 3**

Entry	Name	Structure
133	2-chloro-4-[1-methyl-8-[(1-methylethyl)oxy]-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
134	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(2-methylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
135	2-bromo-5-fluoro-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
136	4-[7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
137	4-[7,8-bis(methyloxy)-1-(trifluoromethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	

**Table 3**

Entry	Name	Structure
138	4-{7,8-bis(methoxy)-1-[(methoxy)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}-2-chlorophenol	
139	2-chloro-4-(1-methyl-3 <i>H</i> -[1,3]dioxolo[4,5- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
140	2-chloro-4-(1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
141	2-chloro-4-(1-methyl-9,10-dihydro-3 <i>H</i> ,8 <i>H</i> -[1,4]dioxepino[2,3- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
142	2-chloro-4-[7-[(difluoromethyl)oxy]-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
143	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{{2-(methyloxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
144	2-chloro-4-(6,9-difluoro-1-methyl-8-{{2-(methyloxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-5-fluorophenol	
145	2-chloro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-7-yl)phenol	
146	2-chloro-5-fluoro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-7-yl)phenol	
147	2-chloro-4-[1-methyl-6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
148	2-bromo-4-(6,9-difluoro-1-methyl-8-{{2-(methoxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-5-fluorophenol	
149	7-(3-chlorophenyl)-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinoline	
150	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
151	2-chloro-4-{1-methyl-7-(methoxy)-8-[(tetrahydrofuran-2-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
152	2-chloro-4-{1-methyl-7-(methoxy)-8-[(tetrahydro-2 <i>H</i> -pyran-2-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
153	2-chloro-4-{1-methyl-7-(methoxy)-8-[(2,2,2-trifluoroethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
154	2-chloro-5-fluoro-4-[9-fluoro-1-methyl-6,7,8-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
155	5-(3-chloro-4-hydroxyphenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
156	6,9-difluoro-5-(2-fluorophenyl)-1-methyl-8-{{(methoxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinoline	
157	2-chloro-4-{8-[(difluoromethyl)oxy]-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
158	2-chloro-4-(6,11-difluoro-1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-5-fluorophenol	
159	4-(1-methyl-3 <i>H</i> -benzo[e]indazol-5-yl)phenol	

**Table 3**

Entry	Name	Structure
160	6-fluoro-7-(2-fluorophenyl)-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinoline	
161	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydro-2 <i>H</i> -pyran-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
162	2-chloro-4-[8-{[2-(ethyloxy)ethyl]oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
164	3-fluoro-4-(6-fluoro-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-7-yl)phenol	
165	2-chloro-5-fluoro-4-(6-fluoro-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-7-yl)phenol	
166	2-chloro-4-[8-(cyclopentyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
167	2-chloro-4-(1-methyl-7-(1-methylethyl)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
168	2-chloro-4-[9-ethyl-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
169	2-chloro-4-(6,9-difluoro-1-methyl-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
170	5-(3-chloro-4-hydroxyphenyl)-8-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-6-ol	
171	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**

Entry	Name	Structure
172	2-chloro-4-(6-fluoro-1-methyl-8,9-bis[{2-(methyloxy)ethyl}oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
173	5-[3-chloro-4-(methyloxy)phenyl]-6-fluoro-1-methyl-7-(methyloxy)-8-[[[(1-methylpiperidin-4-yl)methyl]oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinoline	
174	5-[3-chloro-4-(methyloxy)phenyl]-8-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-6-ol	
176	2-chloro-4-{6-fluoro-1-methyl-7-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
177	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	



**Table 3**

Entry	Name	Structure
178	2-chloro-4-[8-{[2-(diethylamino)ethyl]oxy}-6-fluoro-1-methyl-7-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
179	2-chloro-4-(6-fluoro-1-methyl-7-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
182	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-[[1-(methylpiperidin-4-yl)methyl]oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
183	2-bromo-4-(6-fluoro-1-methyl-9-(methoxy)-8-[[1-(methylpiperidin-4-yl)methyl]oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
184	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methoxy)-8-[[1-(methylpiperidin-4-yl)methyl]oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**

Entry	Name	Structure
185	4-(6-fluoro-1-methyl-9-(methoxy)-8-{{(1-methylpiperidin-4-yl)methyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-2-methylphenol	
186	2-chloro-4-{6,9-difluoro-1-methyl-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
187	2-chloro-4-(8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
188	2-chloro-4-(8-{[2-(diethylamino)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
191	6,9-difluoro-5-(1 <i>H</i> -indol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
193	5-(4-aminophenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	

**Table 3**

Entry	Name	Structure
194	2-chloro-4-(6-fluoro-1-methyl-7-(methoxy)-8-{{2-(4-methylpiperazin-1-yl)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
195	5-(2-amino-1,3-thiazol-5-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
196	2-chloro-4-[8-{{2-(4-ethylpiperazin-1-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
197	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{{2-(4-methylpiperazin-1-yl)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
198	5-(6-aminopyridin-3-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
199	5-(5-amino-2-thienyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	

**Table 3**

Entry	Name	Structure
200	2-chloro-4-[8-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
201	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[3-(4-methylpiperazin-1-yl)propyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
202	6,9-difluoro-5-(1 <i>H</i> -indol-6-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
203	N-[5-(6,9-difluoro-8-hydroxy-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-1,3-thiazol-2-yl]acetamide	
206	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
207	4-[8-({2-[butyl(ethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	

**Table 3**

Entry	Name	Structure
208	4-[8-{{(2 <i>R</i> )-2-amino-3-methylbutyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
209	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{{[2-(1-methylpiperidin-4-yl)ethyl]oxy}}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
210	2-chloro-4-[8-{{(1-ethylpiperidin-4-yl)methyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
212	5-(5-amino-1,3,4-thiadiazol-2-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
213	4-[8-{{(2 <i>R</i> )-2-amino-3,3-dimethylbutyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	

**Table 3**

Entry	Name	Structure
214	2-chloro-4-[6-fluoro-1-methyl-9-(methoxy)-8-({2-[4-(2-methylpropyl)piperazin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
215	2-chloro-4-[8-{[2-(5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
216	2-chloro-4-[6-fluoro-1-methyl-8-({2-[4-(1-methylethyl)piperazin-1-yl]ethyl}oxy)-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
217	4-[8-{{[2-(3-amino-8-azabicyclo[3.2.1]oct-8-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
218	2-chloro-4-[8-{{[2-(1-ethylpiperidin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
219	2-chloro-4-{8-[[2-(diethylamino)ethyl]oxy]-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
220	2-chloro-5-{6-fluoro-1-methyl-9-(methoxy)-8-[(2-pyrrolidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
223	2-chloro-4-{6-fluoro-1-methyl-8-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
224	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(3-pyrrolidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
225	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(3-piperidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
226	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-morpholin-4-ylpropyl)oxy]-3H-pyrazolo[3,4-c]isoquinolin-5-yl}phenol	
227	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](methyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
228	2-chloro-4-[8-({2-[[2-(diethylamino)ethyl](methyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
229	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](ethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
230	4-[8-[(2-{bis[3-(dimethylamino)propyl]amino}ethyl)oxy]-6-fluoro-1-methyl-9-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]-2-chlorophenol	



**Table 3**

Entry	Name	Structure
231	2-chloro-4-[6-fluoro-1-methyl-8-({2-[methyl(1-methylpyrrolidin-3-yl)amino]ethyl}oxy)-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
232	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2S)-2-[(methyloxy)methyl]pyrrolidin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
233	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{{2-(4-pyrrolidin-1-yl)piperidin-1-yl}ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
234	2-chloro-4-[8-{{2-(4-cyclohexylpiperazin-1-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
235	2-[4-(2-{{5-(3-chloro-4-hydroxyphenyl)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-yl}oxy)ethyl)piperazin-1-yl]- <i>N</i> -(1-methylethyl)acetamide	






**Table 3**

Entry	Name	Structure
236	4-[8-{[2-(1,4'-bipiperidin-1'-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
237	2-chloro-4-[6-fluoro-1-methyl-8-{[2-(4-methyl-1,4-diazepan-1-yl)ethyl]oxy}-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
238	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
239	2-chloro-4-[8-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
240	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[2-(thiomorpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
241	2-chloro-4-[8-{{2-(2,6-dimethylpiperidin-1-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
242	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{{2-(octahydroquinolin-1(2 <i>H</i> )-yl)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
243	4-[8-{{2-[bis(1-methylethyl)amino]ethyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
244	4-[8-{{2-{{bis[2-(methyloxy)ethyl]amino}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}-2-chlorophenol	
245	2-chloro-4-[6-fluoro-1-methyl-9-(methyloxy)-8-{{2-(piperidin-1-ylethyl)oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

52. (previously presented) A Compound selected from

9	4-[7,8-bis(methyloxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]benzene-1,2-diol	
19	4-[7,8-bis(methyloxy)-1-(1-phenylethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
24	4-[6,7,8-tris(methyloxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
26	4-[8-(methyloxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
221	6,9-difluoro-5-(2-imino-3-methyl-2,3-dihydro-1,3-thiazol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	

53. (previously presented) A pharmaceutical composition comprising the compound according to claim 31 and a pharmaceutically acceptable carrier.

54. **(withdrawn-currently amended)** A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition according to claim 31.

55. **(withdrawn)** The method according to claim 54, wherein the kinase is ALK.

56. **(withdrawn)** The method according to claim 55, wherein modulating the *in vivo* activity of ALK comprises inhibition of ALK.

57. **(withdrawn-currently amended)** A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in ~~any one of~~ claims claim 31.

58. **(withdrawn)** The method of claim 57 where the disease is an ALK-positive lymphomas, B-cell lymphoma, neuroblastoma, or inflammatory myofibroblastic tumors.